Familial Hypercholesterolemia Homozygous

• CLINICAL_TRIALS trial_result · 2026-02-09
  Clinical Trial Update: Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies [Phase 3]

  This trial update reports long-term safety and tolerability data for inclisiran in participants with familial hypercholesterolemia (heterozy…

• CLINICAL_TRIALS research · 2025-05-09
  Clinical Trial Update: Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry

  A prospective German registry completed that collects data on dyslipidemia treatment indications in patients at very high cardiovascular ris…

• CLINICAL_TRIALS trial_result · 2021-07-01
  Clinical Trial Update: Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia [Phase 2, Phase 3]

  A clinical trial update evaluating efficacy and safety of IBI306 in homozygous familial hypercholesterolemia across Phase 2 and Phase 3 stag…

• CLINICAL_TRIALS trial_result · 2018-10-10
  Clinical Trial Update: Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy [Phase 3]

  Phase 3 trial evaluating lomitapide in Japanese patients with homozygous familial hypercholesterolemia on concurrent lipid-lowering therapy …

• FDA approval · 2016-07-19
  FDA Approved: ROSUVASTATIN CALCIUM — Original Application (Rising Pharma Holdings, Inc.)

  FDA approved an original Abbreviated New Drug Application for rosuvastatin calcium from Rising Pharma Holdings, Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.